Premium
Effect of age and gender on the pharmacokinetics of eprosartan
Author(s) -
Tenero David M.,
Martin David E.,
Miller Ann K.,
Ilson Bernard,
Boike Steven C.,
Zariffa Névine,
Jorkasky Diane K.
Publication year - 1998
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1046/j.1365-2125.1998.00778.x
Subject(s) - pharmacokinetics , medicine , bioavailability , endocrinology , pharmacology
Aims To compare the pharmacokinetics of eprosartan between young (18–45 years) and elderly (65 years) men and between young men and young, premenopausal women (18–45 years).Methods Twenty‐four subjects (eight subjects/group) received a single 200 mg eprosartan oral dose followed by serial blood sampling over 24 h.Results Eprosartan was safe and well tolerated. There were no apparent differences in the pharmacokinetics of eprosartan between young females and young males or in the plasma protein binding of eprosartan (≈98%) for the three groups. On average, AUC (0,∞) and C max values were ≈2‐fold higher in elderly men than young men [AUC (0,∞) 95% CI: 1.22, 4.34; C max 95% CI: 0.98, 4.00]. Similarly, unbound AUC (0,∞) and C max values were, on average, ≈2‐fold higher in elderly men than young men [unbound AUC (0,∞) 95% CI: 1.29, 4.44; unbound C max 95% CI: 1.02, 4.12]. t max was delayed in the elderly men compared with young men, with a median difference of 2.5 h (95% CI: 1.00, 3.01 h).Conclusions No gender differences were observed in the pharmacokinetics of eprosartan. There were ≈ two fold higher AUC and C max values for eprosartan observed in elderly men as compared with young men, most likely due to increased bioavailability of eprosartan in the elderly. Based on the excellent safety profile in the elderly in Phase III clinical trials (doses up to 1200 mg eprosartan) eprosartan can be safely administered to elderly hypertensive patients without an initial dose adjustment. Subsequently, the dose of eprosartan, as for other antihypertensive agents, may be individualized based on tolerability/response.